Fig. 5From: Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialCumulative incidence of overall survival (A), event-free survival (B), relapse(C) and disease-free survival (D) among patients who received or did not receive allo-HSCT. HSCT, hematopoietic stem cell transplantationBack to article page